Market Insight - After the dawn raids
This article was originally published in Scrip
Executive Summary
Controversial from the outset, the European Commission's inquiry into the pharmaceutical sector commenced with unannounced inspections at the offices of innovator and generic companies on January 16th this year. The basis for the inquiry, according to competition commissioner Neelie Kroes, was that "if innovative products are not being produced, and cheaper generic alternatives … delayed, then we need to find out why and, if necessary, take action".